col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


40 Results       Page 1

 [1] 
Elsevier: Journal of Molecular Graphics and Modelling
  original article Date Title Authors   All Authors
1 [GO] 2022―Apr―27 Virtual and biochemical screening to identify the inhibitors of binding between SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2 Chanyoub Park, Changsun Eun
2 [GO] 2022―Apr―21 Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2 Idowu A. Kehinde, Anu Egbejimi, Manvir Kaur, Collins Onyenaka, Tolulope Adebusuyi, Omonike A. Olaleye
3 [GO] 2022―Apr―18 The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling Eleni Pitsillou, Julia Liang, Andrew Hung, Tom C. Karagiannis
4 [GO] 2022―Apr―14 Identification of phytocompounds as newer antiviral drugs against COVID-19 through molecular docking and simulation based study Bipasa Kar, Budheswar Dehury, Mahender Kumar Singh, Sanghamitra Pati, Debdutta Bhattacharya
5 [GO] 2022―Apr―14 Molecular insights into the differential dynamics of SARS-CoV-2 variants of concern Nabanita Mandal, Aditya K. Padhi, Soumya Lipsa Rath
6 [GO] 2022―Apr―12 Molecular modelling identification of phytocompounds from selected African botanicals as promising therapeutics against druggable human host cell targets of SARS-CoV-2 John Omo-Osagie Uhomoibhi, Francis Oluwole Shode, Kehinde Ademola Idowu, Saheed Sabiu
7 [GO] 2022―Jan―05 Molecular dynamics simulations of the flexibility and inhibition of SARS-CoV-2 NSP 13 helicase Bryan A. Raubenolt, Naeyma Islam, Christoper M. Summa, Steven W. Rick
8 [GO] 2021―Dec―21 Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches Shovonlal Bhowmick, Achintya Saha, Nora Abdullah AlFaris, Jozaa Zaidan ALTamimi, Zeid A. ALOthman, Tahany Saleh Aldayel, et al. (+2)
9 [GO] 2021―Oct―14 Predicting novel drug candidates against Covid-19 using generative deep neural networks Santhosh Amilpur, Raju Bhukya
10 [GO] 2021―Oct―12 Small molecule interactions with the SARS-CoV-2 main protease: In silico all-atom microsecond MD simulations, PELE Monte Carlo simulations, and determination of in vitro activity inhibition Julia Liang, Eleni Pitsillou, Katherine Ververis, Victor Guallar, Andrew Hung, Tom C. Karagiannis
11 [GO] 2021―Oct―05 Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease Marina Macchiagodena, Marco Pagliai, Piero Procacci
12 [GO] 2021―Sep―29 In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals Yusuf Şimşek, Sahra Setenay Baran, Belma Aslım
13 [GO] 2021―Sep―17 E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies Wei Bu Wang, Yu Liang, Yu Qin Jin, Jing Zhang, Ji Guo Su, Qi Ming Li
14 [GO] 2021―Sep―09 Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study Saima Reyaz, Alvea Tasneem, Gyan Prakash Rai, Hridoy R. Bairagya
15 [GO] 2021―Jul―28 Structure-based study of immune receptors as eligible binding targets of coronavirus SARS-CoV-2 spike protein Saeed Mobini, Milad Chizari, Ladan Mafakher, Elmira Rismani, Elham Rismani
16 [GO] 2021―Jun―23 Transcription Factor NF-κB as Target for SARS-CoV-2 Drug Discovery Efforts Using Inflammation-based QSAR Screening Model Tarek Kanan, Duaa Kanan, Ebrahim Jaafar Al Shardoub, Serdar Durdagi
17 [GO] 2021―Jun―17 Energetic and structural basis for the differences in infectivity between the wild-type and mutant spike proteins of SARS-CoV-2 in the Mexican population Nazmul Hussain
18 [GO] 2021―Jun―03 Examining the Interactions Scorpion Venom Peptides (HP1x090, Meucin-13, and Meucin-18) with the Receptor Binding Domain of the Coronavirus Spike Protein to design a Mutated Therapeutic Peptide Karim Mahnam, Maryam Lotfi, Farzaneh Ahmadi Shapoorabadi
19 [GO] 2021―Apr―20 Modelling studies reveal the importance of the C-terminal inter motif loop of NSP1 as a promising target site for drug discovery and screening of potential phytochemicals to combat SARS-CoV-2 Dhamodharan Prabhu, Sundaraj Rajamanikandan, Muthusamy Sureshan, Jeyaraman Jeyakanthan, Kadhirvel Saraboji
20 [GO] 2021―Apr―15 In Silico Approach for Identifying Natural Lead Molecules Against SARS-COV-2 Shiv Shankar Gupta, Ashwani Kumar, Ravi Shankar, Upendra Sharma
21 [GO] 2021―Mar―20 Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study Mahmoud A.A. Ibrahim, Eslam A.R. Mohamed, Alaa H.M. Abdelrahman, Khaled S. Allemailem, Mahmoud F. Moustafa, Ahmed M. Shawky, et al. (+4)
22 [GO] 2021―Mar―06 Which Species does the Virus Like Most: Binding Modes Study between SARS-CoV-2 S Protein and ACE2 Receptor Sheng Guo, Jing Yang, Yu Lei, Bin Liu, Wei Zhang, Li Zhang, Zhili Zuo
23 [GO] 2021―Feb―23 Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing Molecular Docking and Molecular Dynamics (MD) Simulations Chirag N. Patel, Dweipayan Goswami, Dharmesh G. Jaiswal, Robin M. Parmar, Hitesh A. Solanki, Himanshu A. Pandya
24 [GO] 2021―Feb―23 Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms Daniel M. Shadrack, Geradius Deogratias, Lucy W. Kiruri, Hulda S. Swai, John-Mary Vianney, Stephen S. Nyandoro
25 [GO] 2021―Feb―05 Epitope mimicry analysis of SARS-COV-2 surface proteins and human lung proteins Sara Morsy, Ahmed Morsy
26 [GO] 2021―Jan―26 Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay Eleni Pitsillou, Julia Liang, Katherine Ververis, Andrew Hung, Tom C. Karagiannis
27 [GO] 2021―Jan―04 A potential solution to avoid overdose of mixed drugs in the event of Covid-19: nanomedicine at the heart of the Covid-19 pandemic Eric Duverger, Guillaume Herlem, Fabien Picaud
28 [GO] 2020―Dec―04 Effect of nelfinavir stereoisomers on coronavirus main protease: molecular docking, molecular dynamics simulation and MM/GBSA study Mohsen Sargolzaei
29 [GO] 2020―Oct―16 Exploring the intrinsic dynamics of SARS-CoV-2, SARS-CoV and MERS-CoV spike glycoprotein through normal mode analysis using anisotropic network model Satyabrata Majumder, Dwaipayan Chaudhuri, Joyeeta Datta, Kalyan Giri
30 [GO] 2020―Oct―13 Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of Coronavirus C.N. Prashantha, K. Gouthami, L. Lavanya, Sivaramireddy Bhavanam, Ajay Jain, R.G. Shakthiraju, et al. (+5)
31 [GO] 2020―Sep―24 Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach Bello Martiniano
32 [GO] 2020―Sep―24 MEDT Study of the 1,3-DC Reaction of Diazomethane with Psilostachyin and investigation about the interactions of some pyrazoline derivatives with Protease (Mpro) of nCoV-2 M. Salah, M.E. Belghiti, A.O. Aitouna, A. Zeroual, S. Jorio, H. El Alaoui Abdellaoui, et al. (+3)
33 [GO] 2020―Sep―21 An in-silico evaluation of COVID-19 main protease with clinically approved drugs Wafa Tachoua, Kabrine Mohamed, Mamona Mushtaq, Zaheer Ulhaq
34 [GO] 2020―Sep―02 Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach Ikechukwu Achilonu, Emmanuel Amarachi Iwuchukwu, Okechinyere Juliet Achilonu, Manuel Antonio Fernandes, Yasien Sayed
35 [GO] 2020―Aug―21 Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2 Manisha Prajapat, Nishant Shekhar, Phulen Sarma, Pramod Avti, Sanjay Singh, Hardeep Kaur, et al. (+5)
36 [GO] 2020―Aug―18 Molecular Modelling Investigation for Drugs and Nutraceuticals against Protease of SARS-CoV-2 Kanchanok Kodchakorn, Yong Poovorawan, Kamol Suwannakarn, Prachya Kongtawelert
37 [GO] 2020―Aug―11 Structural Analysis of Experimental Drugs Binding to the SARS-CoV-2 Target TMPRSS2 David J. Huggins
38 [GO] 2020―Jul―24 Polyacylated anthocyanins constructively network with catalytic dyad residues of 3CLpro of 2019-nCoV than monomeric anthocyanins: A structural-relationship activity study with 10 anthocyanins using in-silico approaches Ibrahim Khalifa, Asad Nawaz, Remah Sobhy, Sami A. Althawb, Hassan Barakat
39 [GO] 2020―Jul―23 Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: insights from a molecular mechanics-assisted structure-based virtual screening experiment Kerem Teralı, Buket Baddal, Hayrettin Ozan Gülcan
40 [GO] 2020―Jul―15 Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation Koichiro Kato, Teruki Honma, Kaori Fukuzawa
 [1] 

40 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.004 sec